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cesses that can occur after hematopoietic stem cell transplantation.
In the allogeneic setting, pulmonary cytolytic thrombi and BOmay
be considered as lung components of acute and chronic graft versus
host disease (GVHD), respectively. Chronic GVHD with pulmo-
nary compromise is associated with high mortality. We report
results in a 6 year-old girl s/p haploidentical peripheral blood stem
cell transplant for biphenotypic acute leukemia. Initial post-trans-
plant course was complicated by aGVHD involving skin and gut.
She also had adenovirus successfully treated with cidofovir (1
mg/kg TIW). She subsequently developed cGVHD of the skin, gut
and lungs.
Pulmonary function deteriorated despite multiple, sequential ag-
gressive immune suppressive regimens including cyclosporine 
prednisone, tacrolimus  mycophenolate  prednisone, and in-
ﬂiximab  dacluzimab  prednisone. cGVHD of the skin and gut
resolved. Clinically, patient had chronic cough and exertional dys-
pnea. Chest CT showed patchy, interstitial pulmonary inﬁltrates.
Bronchoalveolar lavages excluded an infectious etiology. Pulmo-
nary function tests showed increasingly restrictive lung function
(see table below).
Inhaled cyclosporine was based on prior aerosol cyclosporine use
in lung transplantation for prevention and treatment of lung re-
jection (see Burkart GJ et al. Pharm Res 2003;20:252-6 ; Iacono AT
et al. Am J Resp Crit Care Med 1997;155:1690-1698; and Iacono
AT et al. Am J Resp Crit Care Med 1996;153:1451-1455). We
hypothesized that because aerosol cyclosporine can achieve higher
concentrations in the airways with prolonged pulmonary retention
compared to systemic immune suppression, it would be more
effective for cGVHD involving lung. Our goal was sustained pul-
monary improvement with less systemic toxicity.
Inhaled cyclosporine was slowly escalated to 75 mg as an aerosol
qd x 7 days, then tapered to 75 mg 3 times/week for 6 months.
Aerosol lidocaine was used as a pre-medication to prevent airway
irritation. Our patient had near normalization of her pulmonary
function tests after 1 month of aerosol cyclosporine. Treatment
was non-toxic and well tolerated as an outpatient. She continues in
excellent health and has a normal performance status. Thus, in this
patient, inhaled cyclosporine seemed to be a safe and effective
aerosol therapy for cGVHD of the lungs.
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DIFFERENTIAL GENE EXPRESSION PROFILES OF THE CD4CD25 T
SUPPRESSOR (TS) CELL POPULATION IN HUMAN CORD BLOOD AND
ADULT PERIPHERAL BLOOD VS MURINE SPLEEN CELLS
Chang, C.-C., Oberﬁeld, N., Satwani, P., van de Ven, C., Simpson,
L.L., Cairo, M.S. Children’s Hospital of New York-Presbyterian, Co-
lumbia University.
The incidence and severity of acute and chronic GvHD follow-
ing UCB transplant (UCBT) is signiﬁcantly less compared to that
of unrelated adult donor allogeneic stem cell transplant (Cairo et
al, Blood 90:4665, 1997). T suppressor (Ts) cells of the
CD4CD25 subset play a pivotal role in the maintenance of
immune unresponsiveness to allogeneic antigens in GvHD in a
rodent model (Taylor et al, Blood 99:3493, 2002 and Edinger et al.,
Nat Med 9:1144, 2003). We have previously demonstrated an
increase in CD4CD25 cells in CB vs. APB following secondary
alloantigen stimulation (Liu et al, Proc AACR 43:751, 3727a,
2002). In this study, we sought to determine if a group of genes
predominantly expressed in murine CD4CD25 Ts cells might
be used to evaluate the regulatory role of human Ts. CD4 T cells
of both CD25 and CD25- subsets were puriﬁed to 95% homo-
geneity from 4 APB and CB samples. Expression of various Ts
speciﬁc genes was determined by a dilution based semi-quantitative
RT-PCR analysis using CD25 and GAPDH as the internal posi-
tive and negative controls, respectively. Here we report that among
seventeen genes preferentially expressed in murine naive
CD4CD25 T cell subsets but not in activated CD4 T cells,
only eight of them exhibited similar predominant expression in
both human CB and APB Ts cells, including GITR, Foxp3,
CTLA-4, ECM-1, Irf4, Rarg, Rgs1, and Tnfrsf-1B. Expression of
some negative signaling molecules such as SOCS2 (suppressor of
cytokine signaling 2) and the inhibitory receptor PD-1, thought to
mediate the maintenance of the anergic state of Ts, failed to be
ampliﬁed from both CB and APB Ts cells, suggesting that human
Ts cells may require different mechanisms compared to murine Ts
cells to suppress immune responses. Our result identiﬁes a class of
molecules functionally indispensable for mediating inhibitory ac-
tivity of Ts in both humans and rodents. Future studies will
determine their physiological relevance in the context of Ts me-
diated suppression.
113
THE ADDITION OF INTERLEUKIN (IL) -18 TO ANTI-CD3, IL-2 AND
IL-12 FOR EXPANSION AND ACTIVATION OF UMBILICAL CORD BLOOD
(UCB) CYTOTOXIC T-LYMPHOCYTES
Satwani, P., Ayello, J., van de Ven, C., Simpson, L., Cairo, M.S.
Children’s Hospital of New York-Presbyterian, Columbia University,
New York, NY.
A limitation of UCB as a source for adoptive cellular immunity
(ACI) is the limited number of immunoeffector T cell subsets
and/or UCB immaturity. We have previously demonstrated the ex
vivo expansion, maturation, and activation of fresh UCB derived T
lymphocytes with anti-CD3, IL-2, IL-12 and IL-7 (AB/CY) (Rob-
inson/Cairo et al, Exp Hem 30:245, 2001). IL-18 has been shown
to enhance T cell cytolytic activity and provide antitumor immu-
nity (Osaki et al, J Immunol 1998, 160: 1742), in addition to
working synergistically with IL-2 in NK cell proliferation (Son YI
et al, J Immunother, 2003, 26:234). We have shown that IL-18 acts
synergistically with IL-12 to induce NK and LAK cellular cyto-
toxicity in UCB (Cairo et al. J Pediatr Hematol/Oncol 2003;
25(4):8, p. S2.). For this study, we compared the expansion, mat-
uration, activation, and cell survival of UCB in IL-18 with the
AB/CY combination without IL-7. UCB MNCs were isolated by
Ficoll density centrifugation and incubated overnight @ 37°C, 5%
CO2 in serum free (SF) AIM-V media. The nonadherent MNC
fraction was cultured in SF AIM-V media alone and with IL-2 (5
ng/ml), IL-12 (10 ng/ml), anti-CD3 (50 ng/ml) and IL-18 (10
ng/ml) for 48 hours @ 5% CO2, 37°C. Expression of T cell
receptors was analyzed by ﬂow cytometry using CD3, CD45RO,
CD8, CD4, CD25, CD16, and CD56 monoclonal antibodies.
Apoptosis markers were determined by measuring Annexin V and
PI by ﬂow cytometry. Expression of lymphocyte subsets of CD8/
25 , CD4/25 and CD16/56 was signiﬁcantly increased in
the AB/CY with IL-18 compared to media alone (CD8/25:
58.416.4 vs 28.813.9%, p  0.05; CD4/25: 61.4  4.4 vs
2.9  0.9, p  0.001; CD16/56: 57.913.0 vs 24.07.1%, p 
0.05, respectively). There was no signiﬁcant increase in the CD3/
45RO activation when compared to media alone. To determine if
the increases were due in part to increased cell survival, AB/CY
with IL-18 expanded cultures demonstrated no signiﬁcant differ-
ence in apoptotic markers compared to media alone. In comparison
to historical data, there was no signiﬁcant difference in AB/CY
with IL-7 vs. AB/CY cocktail with IL-18. These data suggests that
CD8/25, CD4/25 and CD16/56 subsets can be ex vivo
expanded with AB/CY with IL-18 for possible use in ACI for DLI
after UCBT. In vitro functional and in vivo xenotransplant studies
are underway to further examine the cytolytic activity of these
activated UCB cell subsets.
Table. Pulmonary Function Tests: Before vs After Aerosol
Cyclosporine
Dates VC FVC FEV1 FEF 25–75
9/26/02 57% 56% 57% 38%
12/2/02 49% 48% 48% 20%
1/7/03 68% 63% 61% 26%
1/14/03 84% 84% 62% 30%
2/17/03 93% 92% 92% 59%
5/20/03 93% 94% 88% 46%
Values: % predicted; 1/10/03—began aerosol cyclosporine.
Poster Session I
46
